# Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

> **NCT06611891** · PHASE3 · RECRUITING · sponsor: **University Hospital, Grenoble** · enrollment: 25 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** 68Ga-DOTATOC

## Key facts

- **NCT ID:** NCT06611891
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2025-10
- **Final completion:** 2026-10
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06611891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06611891, "Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06611891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*